spacer
home > ebr > summer 2007 > manage risk, manage the regulator
PUBLICATIONS
European Biopharmaceutical Review

Manage Risk, Manage the Regulator

Risk management is the smart route to safety and well-aimed investment. In the increasingly competitive life sciences sector, Oliver Steck and Richard Petherick, at WCI Consulting Ltd, explain that picking up potential risks before they become a danger to the patient is imperative and has just been enforced by recent regulations

The traditional approach of pure compliance to regulations using a typically paperheavy system will probably keep you on the right side of the regulators – but, will it help you to improve your processes? The public demands a demonstrable increase in safety – no wonder the regulators are looking for a new approach! The traditional approach does not increase safety, nor does it deliver better or faster drug development, which ought to be one of the required outputs. Ultimately, the defect of the traditional approach is that, although it uses immense resources, it addresses the letter but not the spirit of regulations.

Shareholders are most likely to agree. Get caught putting profits before patient safety and nobody will trust you again. And trust is an issue that is right at the core of life sciences – once lost, trust is nearly impossible to recover.

FLEXIBILITY

The stakeholders seem to have a shared interest in a more flexible and sophisticated regulatory process. The industry must be ever aware of all its stakeholders. That includes patients, both those whose lives are being saved now and those yet to be saved. When everyone can see the point of a change, the law – patent, regulation – will follow. As a patient we want remedies that are effective, free of side effects, cheap and simple to use. The more serious our illness, the more important effectiveness becomes. The new, outcome-focused approach – where you are accountable for your serious adverse events (SAEs) whether technically compliant or not – is welcome in principle, but it needs to be backed by a systematic methodology.

That methodology is, without question, risk management and the accompanying IT – the smarter route to fewer adverse events (AEs), safer drugs and well aimed investment. But it is easy to do it superficially, endangering public safety, and regulators fear life science companies will use it as a shortcut to compliance. What it requires as a regulation tool is involvement and understanding from professional-level regulators rather than administration-level bureaucrats.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Oliver Steck is a Managing Consultant with WCI Consulting Ltd. Since joining the organisation three years ago, Oliver has helped life science clients optimise their processes with regards to content management, compliance-related issues and risk management. Oliver holds a degree in Medical Computer Science from the University of Heidelberg and the Polytechnic University Heilbronn.

Richard Petherick is a Senior Consultant with WCI Consulting Ltd. He has 10 years of experience working in the quality arena of the life science industry, both in manufacturing and corporate roles. Richard’s areas of expertise include regulatory compliance, risk management, project management and quality assurance.

spacer
Oliver Steck
spacer
spacer
spacer
Richard Petherick
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Signant Health Appoints Todd Everhart as Clinical Vice President to Accelerate Intelligent eCOA and Predictive Data Analytics in Medical Clinical Research

PHILADELPHIA, PA – August 20, 2019: Signant Health, formerly CRF Health and Bracket, has appointed Anthony Todd Everhart, MD, FACP to the Signant Health Science and Medicine Team as Clinical Vice President, Internal Medicine, reporting to the Chief Medical Officer, Dr. David Daniel.
More info >>

White Papers

A Rules Based Approach to Labelling and Artwork Management

Kallik

Many organisations today are experiencing unprecedented demands from regulatory authorities and consumers alike for product labelling to be made clearer and more informative. Forthcoming regulations (including the new EU MDR regulations coming into force May 2020) also require that labelling content to be published electronically in addition to print. As companies seek to continuously differentiate themselves in established markets as well as gain entry into new territories, the increase in both volume and complexity of product and market variations will have a direct impact on labelling.
More info >>

 
Industry Events

CPhI & P-MEC India

26-28 November 2019, India Expo Centre, Greater Noida, Delhi NCR, India

As the pharma industry looks increasingly towards India for high quality, low cost pharma solutions, CPhI & P-MEC India is the ideal event for companies wanting to pick up on the latest trends and innovations the market has to offer. At CPhI & P-MEC India, you will meet the movers and shakers from India's pharma machinery, technology and ingredients industries, giving you a competitive advantage that will help grow your business.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement